At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 59 enrolled
Drug / intervention
Tocilizumab +1 moredrug
Likely dose
Tocilizumab 8mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
In Brief
A Phase 4 clinical trial evaluating Tocilizumab and Placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 59 participants across 1 site.
Detailed Summary
Randomized, double-blind clinical trial of tocilizumab vs. placebo as add-on treatment for residual positive, negative, and cognitive symptoms in schizophrenia. The primary study hypothesis is that individuals receiving tocilizumab will show greater improvements in their PANSS total scores than those taking placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsStanley Medical Research Institute
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartFeb 2014
Primary CompletionFeb 2017
TodayJul 2026
First PostedJan 13, 2014
Enrollment StartFeb 1, 2014
Primary CompletionFeb 6, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 12.5 years ago
Interventions
Tocilizumabdrug
8mg/kg intravenously via iv drip over 60 min
Placebodrug
intravenously via iv drip over 60 min